Cognition Therapeutics Announces Issuance of Composition of Matter Patent, Extending Protection for Zervimesine (CT1812) Through 2045
Cognition Therapeutics was granted a U.S. composition-of-matter patent covering a novel crystalline polymorph of zervimesine (CT1812), its lead drug candidate, with natural expiration in 2045 and potential for up to five additional years upon FDA approval. The patented form has an enhanced pharmaceutical profile suited to large-scale manufacturing for Phase 3 and commercialization, and management plans to begin manufacturing it in Q1 2027.
Key figures
- Drug Name
- zervimesine (CT1812)
- Phase Of Trial
- Phase 2
- Patent number
- U.S. Patent No. 12,759,979
- Nih grant funding
- nearly $200 million
- Patent expiration
- 2045 (up to five additional years possible upon FDA approval)
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.